ReviewThe British journal of radiology2024
Hepatocellular adenoma update: diagnosis, molecular classification, and clinical course.
Review in The British journal of radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of ADC in differentiating hepatocellular adenoma vs. hepatocellular carcinoma and metastatic liver lesions: systematic review and meta-analysis.Abdominal radiology (New York) · 2026Pooled it
- Multifocal hemorrhagic hepatocellular adenomas following vigorous physical exertion: Radiologic-pathologic correlation and endovascular management.Radiology case reports · 2026Article
- Differentiating focal nodular hyperplasia from hepatic adenoma using a multimodality approach in children.Pediatric radiology · 2026Review
- Gravitational 3D Magnetic Resonance Elastography for Differentiating Focal Nodular Hyperplasia and Hepatic Adenoma.Diagnostics (Basel, Switzerland) · 2026Article
- New histopathological terminology for well-differentiated hepatocellular lesions in unusual clinico-pathological scenarios: HCA-like and FNH-like.JHEP reports : innovation in hepatology · 2026Review
- Hyperintense liver lesions on hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging: clinical insights and significance.Abdominal radiology (New York) · 2026Review
- Hyperintense liver lesions on hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging: clinical insights and significance.Abdominal radiology (New York) · 2026Review
- Article
- Potential to Avoid Invasive Procedures for Atypical Focal Nodular Hyperplasia (FNH) and FNH-like Lesions Based on MR Findings.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Article
- Giant Atypical Hepatocellular Adenoma of Unknown Etiology in a Young Male: A Case Report.Journal of hepatocellular carcinoma · 2026Article
- A Case Report of an Inflammatory Hepatocellular Adenoma Mimicking Hepatocellular Carcinoma in a Patient with Alcoholic Cirrhosis.Current medical imaging · 2026Article
- Diagnosis and Management of Benign Liver Tumors.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular adenomas (HCA) are acquired focal liver lesions, that occur mainly in young-to-middle-aged women who are on long-term estrogen-containing contraceptives or young men after prolonged use of anabolic steroids. Furthermore, distinct underlying diseases, such as obesity, metabolic dysfunction-associated steatotic liver disease, glycogen storage disease, etc. are considered risk factors. The 2017 Bordeaux classification, in particular Nault et al, divided HCAs into eight subtypes according to their pheno- and genotypic characteristics. This includes HCAs with hepatocyte-nuclear-factor (HNF1-alpha mutation), HCAs with β-catenin mutation, and HCAs without either of these genetic mutations, which are further subdivided into HCAs with and without inflammatory cells. HCAs should no longer be classified as purely benign without histologic workup since three of the eight subtypes are considered high-risk lesions, requiring adequate management: malignant transformation of the pure (ßex3-HCA) and mixed inflammatory/β-catenin exon 3 (ßex3-IHCA) adenomas, as well as potential bleeding of the sonic hedgehog HCA and pure (ßex7/8-HCA) and mixed inflammatory/β-catenin exon 7/8 (ßex7/8-IHCA). Elective surgery is recommended for any HCA in a male, or for any HCA exceeding 5 cm. Although MRI can classify up to 80% of adenomas, if findings are equivocal, biopsy remains the reference standard for adenoma subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.